OrthoPediatrics Corp. filed an 8-K to disclose an investor presentation dated August 2026, furnished under Regulation FD for use in upcoming analyst and investor meetings. The presentation outlines the company's strategic pillars, product innovation roadmap, and financial performance through the second quarter of 2026. Key figures include $236.3 million in full-year 2025 revenue, a 15% growth rate, and an adjusted EBITDA loss of $7.2 million for Q2 2026. Management provided FY2026 guidance projecting revenue between $265.0 million and $269.0 million with approximately $25.0 million in adjusted EBITDA breakeven. The company operates in the medical device industry, specifically developing and commercializing specialized orthopedic products for pediatric patients.